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Abstract: Literature indicates that peptic and tryptic peptides derived from the enzymatic hydrolysis
of lupin protein are able to modulate cholesterol metabolism in human hepatic HepG2 cells and
that part of these peptides are absorbed in a small intestine model based on differentiated human
Caco-2 cells. In this paper, a co-culture system, including Caco-2 and HepG2 cells, was investigated
with two objectives: (a) to verify whether cholesterol metabolism in HepG2 cells was modified
by the peptides absorption through Caco-2 cells; (b) to investigate how lupin peptides influence
cholesterol metabolism in Caco-2 cells. The experiments showed that the absorbed peptides, not
only maintained their bioactivity on HepG2 cells, but that this activity was improved by the crosstalk
of the two cells systems in co-culture. In addition, lupin peptides showed a positive influence on
cholesterol metabolism in Caco-2 cells, decreasing the proprotein convertase subtilisin/kexin type 9
(PCSK9) secretion.
Keywords: bioactive food peptides; cholesterol metabolism; intestinal absorption; LDL receptor;
Lupinus; PCSK9
1. Introduction
Lupin seed is gaining increasing attention due to its nutritional features, in particular the
abundance of protein with a favourable essential amino acid composition [1], unsaturated fatty
acids, fibre, minerals, carotenoids, tocoferols [2], and polyphenols [3], whereas isoflavones content is
negligible [4]. Moreover, different studies have shown that lupin consumption provides useful health
benefits [5], particularly in the area of hyperglycaemia prevention [6,7], hypertension control [8,9],
and cholesterol reduction. This activity has been investigated in animal models, such as rat [10,11],
rabbit [12], and hamster [13], and in clinical trials [14,15].
In particular, a study performed in human hepatic HepG2 cells has provided information on
the lupin seed components responsible for the hypocholesterolaemic activity and the molecular
mechanisms involved [16]. Tryptic and peptic peptides obtained by enzymatic hydrolysis of lupin
protein inhibit the activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCoAR),
up-regulate the low density lipoprotein receptor (LDLR) and sterol regulatory element binding protein
2 (SREBP-2), and increase the LDL-uptake. In addition, other evidences suggest that lupin protein can
modulate the production of proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein which
is correlated to atherosclerosis progression and is, therefore, a novel target for hypocholesterolaemic
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drugs [17–20]. In fact, after consuming dietary bars containing lupin protein (30 g) for four weeks,
mild hypercholesterolaemic subjects showed an 8.5% decrease of plasma PCSK9 levels, positively
associated with lower levels of total plasma cholesterol, compared to the control subjects who
consumed bars containing casein (30 g) [21]. Moreover, in vitro experiments performed on HepG2 cells
have demonstrated that peptic and tryptic peptides obtained by hydrolysis of lupin protein positively
affect the LDLR pathway, reducing PCSK9 protein levels and secretion as well as inhibiting hepatic
nuclear factor 1 alpha (HNF-1 alpha) [21].
Intestinal bioavailability is critical for dietary bioactive compounds and can be investigated
in vitro by conducting trans-epithelial transport experiments across a monolayer of differentiated
human intestinal Caco-2 cells. In fact, these cells spontaneously differentiate in culture, expressing
several morphological and functional characteristics of mature small intestinal enterocytes [22,23].
This intestinal model has extensively been used for investigating the absorption of different food
components, peptides included [24]. To investigate the absorption of lupin peptides, in a previous
work Caco-2 cells differentiated in a two-compartment system were treated with peptic or tryptic lupin
peptides in the apical (AP) compartment, and the peptides passing in the basolateral (BL) compartment
were analyzed and shown to express a moderately improved inhibitory activity on the catalytic site of
HMGCoAR compared to the starting peptide mixtures [25].
In this context, the main goal of the present work was to evaluate whether the lupin peptides
absorbed across Caco-2 cells still maintain their hypocholesterolaemic effect on hepatocytes, i.e., the
major cells involved in the clearance of plasma LDL cholesterol [26,27]. To achieve this objective,
human intestinal cells and human hepatic cells were combined in a co-culture model (Figure 1), in
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Figure 1. Schematic representation of the co-culture model. Caco-2 cells were grown and differentiated
on polycarbonate filter membranes for 21 days. Confluent human hepatic HepG2 cells were seeded in
6-wells culture plates in complete medium. For co-culture experiments, filter inserts with differentiated
Caco-2 cells were transferred to wells containing hepatic cell cultures and treated with lupin peptides
for 24 h in the apical chamber. AP: Apical side, BL: Basolateral side.
HepG2 cells were selected as the hepatic cell line, since the same model had been previously
used for the characterization of the molecular mechanism through which tryptic and peptic lupin
peptide mixtures mediate their hypocholesterolaemic effects [16]. Another goal of this work was
to verify whether lupin peptides could affect cholesterol metabolism in differentiated Caco-2 cells,
by specifically investigating the modulation of the LDLR-SREBP2 pathway and PCSK9 production.
In fact, there is increasing evidence that, in addition to being involved in the uptake of cholesterol,
the small intestine can also actively sec ete this molecule, with a mechanism named tran -intestinal
chole terol efflux (TICE) pathway [28], which contribu es in significant way to the o al fecal neutral
sterol excretio together with the better-kn wn hepatobiliary r te [29,30]. Although further research
is necessary for a better understanding of the mechanistic details of the TICE pathway, its therapeutic
potential in the treatments of atherosclerosis appears to be encouraging [28]. The Caco-2 cell model is
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appropriate for investigating the in vitro effects of lupin peptides on the LDLR/SREBP2 pathway in
the intestine.
2. Materials and Methods
2.1. Chemicals and Reagents
Dulbecco’s modified Eagle’s medium (DMEM) was bought from GIBCO (Thermo Fisher Scientific,
Waltham, MA, USA). Fetal bovine serum (FBS) was from Hyclone Laboratories (Logan, UT, USA).
Stable L-glutamine, 1% non-essential amino acids, penicillin/streptomycin, and chemiluminescent
reagent were from Euroclone (Milan, Italy). Polycarbonate filters, 12 mm diameter, 0.4 µm pore
diameter were from Transwell Corning Inc. (Lowell, MA, USA). Phenol red, PBS, bovine serum albumin
(BSA), RIPA buffer, and the antibody against β-actin were from Sigma-Aldrich (St. Louis, MO, USA).
The antibody against HMGCoAR was bought from Abcam (Cambridge, UK), that against PCSK9
from GeneTex (Irvine, CA, USA), that against phospho-HMGCoAR (Ser872) from Bioss Antibodies
(Woburn, MA, USA), and that against LDLR from Pierce (Rockford, IL, USA). The antibodies against
SREBP-2, rabbit Ig-HRP, mouse Ig-HRP, phenylmethanesulfonyl fluoride (PMSF), Na-orthovanadate
inhibitors were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA); the inhibitor
cocktail Complete Midi from Roche (Basel, Switzerland). Mini protean TGX pre-cast gel 7.5% and
Mini nitrocellulose Transfer Packs were purchased from BioRad (Hercules, CA, USA). The human
proprotein convertase 9 immunoassay (Quantikine ELISA) was bought from R & D System
(Minneapolis, MN, USA).
2.2. Preparation of Peptic and Tryptic Peptide Mixtures
Lupin seeds (Lupinus albus cultivar Ares) were provided by Terrena (Matrignè-Ferchaud, France).
Procedures for the preparation of total protein extract, hydrolysis of the protein with pepsin or trypsin
to produce peptic and tryptic peptides, and analytical method by nano-HPLC-ESI-MS/MS have been
previously reported [16,21].
2.3. Cell Culture and Differentiation
Caco-2 cells, obtained from INSERM (Paris) were routinely sub-cultured at low density (50%) [31]
and maintained at 37 ˝C in a 90%/10% air/CO2 atmosphere in DMEM containing 25 mM glucose,
3.7 g/L NaHCO3, 4 mM stable L-glutamine, 1% non-essential amino acids, 100 U/L penicillin, 100 µg/L
streptomycin (complete medium), supplemented with 10% heat inactivated fetal bovine serum (FBS)
(Hyclone Laboratories, Logan, UT, USA). For differentiation, cells were seeded on polycarbonate
filters, 12 mm diameter, 0.4 µm pore diameter (Transwell, Corning Inc., Lowell, MA, USA) at a
3.5 ˆ 105 cells/cm2 density in complete medium supplemented with 10% FBS in both AP and BL
compartments for 2 days to allow the formation of a confluent cell monolayer. Starting from the third
day after seeding, cells were transferred to complete medium in both compartments, supplemented
with 10% FBS only in the BL compartment, and allowed to differentiate for 21 days with regular
medium changes three times weekly [32].
The HepG2 cell line was bought from ATCC (HB-8065, LGC Standards, Milan, Italy). The HepG2
cell line was cultured in DMEM high glucose with stable L-glutamine supplemented with 10% FBS,
100 U/mL penicillin, 100 µg/mL streptomycin (complete growth medium) and incubated at 37 ˝C
under 5% CO2 atmosphere. Caco-2 and HepG2 cells were used for no more than 20 passages after
thawing, as the increase in the number of passages may change the cell characteristics and impair
assay results.
2.4. Cell Treatments with Lupin Peptides
The treatments with lupin peptides were conducted on 21-days differentiated intestinal Caco-2
cells, alone or in co-culture with HepG2 cells at the bottom of the culture plate (Figure 1). For co-culture
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experiments, Caco-2 cells on filter inserts were transferred in multiwell culture plates containing
confluent HepG2 cells. Prior to treatment with lupin peptides, differentiated Caco-2 cells were washed
twice with 500 µL PBS with 1 mM Ca2+ and 1 mM Mg2+. The peptic or tryptic digests of lupin
protein (1.0 µg/µL) were added in the complete medium (500 µL) of the AP compartment, whereas
the BL compartment contained complete medium supplemented with 10% FBS (700 µL). After 24 h
incubation of cells alone or in co-culture, AP and BL media and all cells were collected for further
analysis. Three independent experiments were conducted either on intestinal Caco-2 cells alone or
in co-culture, each in duplicate. The concentration of the peptides in the AP and BL solutions were
determined as indicated in a previous paper [25].
2.5. Cell Monolayer Integrity and Differentiation Evaluation
In order to evaluate the degree of Caco-2 cell differentiation and the integrity of the cell monolayer,
trans-epithelial electrical resistance (TEER) was measured at 37 ˝C using the voltmeter apparatus
Millicell (Merck Millipore Co., Darmstadt, Germany), immediately before and at the end of 24 h
incubation with the tryptic and peptic peptides. After peptides incubation, no significant changes in
TEER values were observed.
2.6. Western Blot Analysis
After 24 h incubation, Caco-2 cells and, in co-culture experiments, also HepG2 cells were scraped in
100 µL of ice-cold lysis buffer (RIPA buffer + inhibitor cocktail + 1:100 PMSF + 1:100 Na-orthovanadate)
and transferred in ice-cold microcentrifuge tubes. After centrifugation at 16,060 g for 15 min at
4 ˝C, the supernatant was recovered and transferred in a new ice-cold tube. Total proteins were
quantified by the Bradford method and 50 µg of total proteins loaded on a pre-cast 7.5% sodium
dodecyl sulphate—polyacrylamide (SDS-PAGE) gel at 130 V for 45 min. Subsequently, the gel was
transferred to a nitrocellulose membrane (Mini nitrocellulose Transfer Packs), using a Trans-blot Turbo
at 1.3 A, 25 V for 7 min. Target proteins, on milk blocked membrane, were detected by primary
antibodies as follows: anti-SREBP2, anti-LDLR, anti-HMGCoAR, anti-phospho-HMGCoAR (Ser872),
anti-PCSK9, and anti-β-actin. Secondary antibodies conjugated with HRP, a chemiluminescent reagent,
were used to visualize target proteins, and their signal was quantified using the Image Lab Software
(Biorad, Hercules, CA, USA). The internal control β-actin was used to normalize loading variations.
2.7. Quantification of Excreted PCSK9 in Cell Culture Experiments by ELISA
The AP and BL media collected from treated Caco-2 cells were centrifuged at 600 g for 10 min
at 4 ˝C, then recovered in a new ice-cold tube. PCSK9 was quantified by ELISA (R & D System).
The lower limit of detection was 0.096 ng/mL
2.8. Statistically Analysis
Statistical analyses were carried out by one-way ANOVA using the software Prism 6 (GraphPad,
La Jolla, CA, USA) followed by Dunnett’s test. Values were expressed as means ˘ SEM; p-values < 0.05
were considered to be significant.
3. Results
3.1. Absorbed Lupin Peptides Maintain the Capacity to Induce the Up-Regulation of LDLR-SREBP2 Pathway
in HepG2 Cells
In a previous paper we have demonstrated that when digested lupin proteins are applied to
the AP surface of a monolayer of differentiated intestinal Caco-2 cells, a certain number of peptides
are transferred intact to the BL compartment and these peptide mixtures retain the ability to inhibit
HMGCoA in vitro activity [25]. In order to evaluate whether the absorbed peptides maintain their
capacity to modulate cholesterol metabolism in hepatocytes, a co-culture system was set up combining
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differentiated Caco-2 cells cultured on filter inserts and hepatic HepG2 cells grown at the bottom
of the culture plates (Figure 1). After treating the intestinal cells with 1.0 µg/µL peptic or tryptic
peptides from the AP side for 24 h, the underlying HepG2 cells in co-culture were harvested to
assess by immunoblotting the expression of target proteins. Figure 2a–c shows that the treatment of
intestinal cells with both peptide mixtures induced an up-regulation of the protein level of SREBP2
N-terminal fragment (mature form with a molecular weight of 68 kDa) in the underlying HepG2 cells
in co-culture. In particular, peptic peptides up-regulated the mature SREBP2 protein level by 102%
versus the untreated cells and tryptic peptides by 104%. In the same experiments, both peptic and
tryptic peptides increased LDLR and HMGCoAR protein levels, in agreement with their capacity to
up-regulate the level of mature-SREBP2 protein. LDLR protein levels were increased by 100% with
peptic peptides and by 266% with tryptic peptides versus the untreated cells (Figure 2b,c), whereas
peptic peptides enhanced the production of the HMGCoAR protein by 73% and tryptic peptides by
108% versus the untreated cells (Figure 2a,c). Finally, both peptide digests increased the inactive
phosphorylated form of HMGCoAR, i.e., p-HMGCoAR: peptic peptides by 90% and tryptic peptides
by 87% versus untreated cells, respectively (Figure 2a,c).
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3.2. Lupin Peptides Mediate the Up-Regulation of LDLR-SREBP2 in Human Intestinal Cells
To assess whether lupin peptides in the same co-culture system could also modulate cholesterol
pathways in the enterocytes, differentiated Caco-2 cells were treated with peptic and tryptic lupin
digests in the AP compartment for 24 h. Immunoblotting experiments showed that this treatment
induced increments of the protein level of SREBP2 N-terminal fragment (mature form with a molecular
weight of 68 kDa), of 195% and 125%, versus the untreated cells, for peptic and tryptic lupin peptides,
respectively (Figure 3a,b). In addition, increased LDLR and HMGCoAR protein levels were observed:
Peptic and tryptic peptides up-regulated LDLR by 143% and 167%, respectively, versus the untreated
cells, and they increased HMGCoAR by 84% and 115%, respectively, versus the control. Finally, peptic
and tryptic peptides increased also the inactive phosphorylated form of HMGCoAR by 41.3% and
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Figure 3. After differentiation on polycarbonate filter membranes for 21 days, Caco-2 cells were
transferred on HepG2 cells and human intestinal cells were treated with 1.0 µg/µL of peptic peptides
(P) or tryptic peptides (T) for 24 h, respectively. The second day, treated Caco-2 cells were harvested and
processed for immunoblotting experiments. SREBP-2, LDLR, HMGCoAR, pHMGCoAR (Ser872), and
β-actin immunoblotting signals were detected using specific anti-SREBP-2, anti-LDLR, anti-HMGCoAR,
anti-pHMGCoAR (Ser872), and anti-β-actin primary antibodies, respectively (a); Each protein signal
was quantified by ImageLab software (Biorad) and normalised with β-actin signals (b). Bars represent
averages of duplicate samples ˘ SEM of three independent experiments. (*) p < 0.05 and (**) p < 0.01
versus untreated sample (C).
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mature SREBP2 protein levels by 112%, and 179%, respectively (Figure 4a–c), and LDLR protein by
58% and 54%, respectively, versus the untreated cells (Figure 4a–c). Increases of HMGCoAR protein
levels by 60% after peptic and by 74% after tryptic peptides treatment, versus the control, were also
observed (Figure 4a–c), accompanied by concomitant increases of the inactive p-HMGCoAR form by
83% for peptic and by 125% for tryptic peptides, versus the untreated cells (Figure 4b,c).Nutrients 2016, 8, 437  7 of 13 
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Figure 4. After differentiation on polycarbonate filter membranes for 21 days, Caco-2 cells were treated
with 1.0 µg/µL of peptic peptides (P) or tryptic peptides (T) for 24 h, respectively. The second day,
Caco-2 cells were harvested and processed for immunoblotting experiments. SREBP-2 (a), LDLR (a),
HMGCoAR (a), pHMGCoAR (Ser872) (b), and β-actin (a,b) immunoblotting signals were detected
using specific anti-SREBP-2, anti-LDLR, anti-HMGCoAR, anti-pHMGCoAR (Ser872), and anti-β-actin
primary antibodies, respectively; Each protein signal was quantified by ImageLab software (Biorad)
and normalised with β-actin signals (c). Bars represent averages of duplicate samples ˘ SEM of three
independent experiments. (*) p < 0.05 and (**) p < 0.01 versus untreated sample (C).
3.3. Lupin Peptides Decrease the Ability of Caco-2 Cells to Secrete PCSK9 in the BL Medium
In Caco-2 cells cultured alone, immunoblotting and ELISA experiments were carried out in order
to assess whether peptic and tryptic lupin peptides were able to affect the levels of intracellular and
secreted PCSK9 in enterocytes. Intracellular PCSK9 protein levels in Caco-2 cells were not significantly
affected by 24-h incubation with peptic and tryptic lupin peptides in the AP compartment (Figure 5a,b).
In order to evaluate whether the secretion of mature PCSK9 was affected by lupin peptides
treatment, and in which direction, its concentration was measured by a specific ELISA in the AP and
BL media at the end of the experiment. Lupin peptides treatment resulted in a significant reduction
in the secretion of mature PCSK9 in the BL compartment, versus untreated cells (Table 1). More in
detail, untreated Caco-2 cells secreted 5.0 ng/mL of mature PCSK9, whereas those treated with peptic
peptides secreted 4.1 ng/mL PCSK9 and those treated with tryptic lupin peptides secreted 3.2 ng/mL
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PCSK9, respectively. Conversely, no mature PCSK9 secretion was detected in the AP compartment,
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slightly lower than those in isolated HepG2 cells, i.e., SREBP‐2 148%, LDLR 136%, HMGCoAR 73% 
[16],  surprisingly,  in  the  case  of  tryptic  peptides,  the  values  observed  in  the  co‐culture  system 
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Figure 5. Immunoblotting experiments were carried out in order to assess whether peptic and tryptic
lupin peptides are able to affect the PCSK9 protein levels. After differentiation on polycarbonate filter
membranes for 21 days, Caco-2 cells alone were treated with 1.0 µg/µL of peptic peptides (P) or tryptic
peptides (T) for 24 h, respectively. The second day, Caco-2 cells were harvested and processed for
immunoblotting experiments (a,b). Mature PCSK9 (PCSK9-M) and β-actin immunoblotting signals
were detected using specific anti-PCSK9-M and anti-β-actin primary antibodies, respectively (a);
Each protein signal was quantified by ImageLab software (Biorad) and normalised with β-actin
signals (b). Bars represent averages of duplicate samples ˘ SEM of three independent experiments.
Ns: not significant.
Table 1. PCSK9 secreted by differentiated Caco-2 cells treated with lupin peptides (1.0 µg/µL) in the
AP chamber, quantified by ELISA (LOD, limit of detection = 0.096 ng/mL).
Parameter C Peptic Peptides Tryptic Peptides
creted PCSK9 in BL solution (ng/mL) 4.82 ˘ 0.35 4.10 ˘ 0.46 * 3.20 ˘ 0.25 **
Secreted PCSK9 in AP solution (ng/mL) <LOD <LOD <LOD
* p < 0.05 vs. untreated sample (C); ** p < 0.01 vs. untreated sample (C).
4. Discussion
4.1. Absorbed Lupin Peptides Maintain Their Hypocholesterolaemic Activity on Human Hepatic HepG2 Cells
Grown in a Co-Culture System
A preceding work [25] has provided evidence that lupin peptides transported from the AP to the
BL compartment in Caco-2 cells maintain intact their initial capacity of inhibiting the enzymatic activity
of HMGCoAR. This has stimulated us to evaluate whether the absorbed lupin peptides were still able
to modulate cholesterol metabolism in hepatic cells, by utilizing a co-culture system, in which human
enterocytes and hepatocytes were combined in order to reproduce as far as possible the tissue crosstalk
occurring in vivo. Indeed, results indicated that the treatment of Caco-2 cells with lupin peptides in
the AP compartment produced a favorable modulation of the LDLR pathway in HepG2 cells cultured
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at the bottom of the BL compartment. In fact, absorbed peptides increased mature SREBP2 protein
level, with the consequent up-regulation of LDLR and HMGCoAR protein levels. Whereas in the
case of peptic peptides, the values observed in the co-culture system were slightly lower than those
in isolated HepG2 cells, i.e., SREBP-2 148%, LDLR 136%, HMGCoAR 73% [16], surprisingly, in the
case of tryptic peptides, the values observed in the co-culture system indicated an improvement of
LDLR pathway activation compared to the values observed in isolated Hep2 cells, i.e., SREBP-2 73%,
LDLR 84%, HMGCoAR 97% [16]. Although, the peptide mixture was, in the case of the co-culture
system, selectively “filtered” by the passage across the Caco-2 cell monolayer, while it was unmodified
when directly applied to HepG2 cultured alone, these comparisons highlight important differences
in the activity of absorbed peptides form lupin digestion. These results suggest in fact a selective
absorption of more active peptides from the tryptic digest, favoring a stronger positive modulation of
cholesterol metabolism.
Finally, it is important to observe that the up-regulation of the HMGCoAR protein level is
not expected to exert a negative effect on cholesterol metabolism, since it can be accounted for by
the increase of the inactive Ser872-phosphorylated species (Figure 2). This is in agreement with
the effects observed in HepG2 cells cultured alone, where the direct treatment with lupin peptides
(1.0 µg/µL) induced an increase in the enzymatically inactive phosphorylated form of HMGCoAR
(Ser872) by 101% with peptic and by 190% with tryptic digests, versus untreated cells (Figure A1 in
Appendix A materials).
4.2. Role of Lupin Peptides in the Regulation of Cholesterol Metabolism in Human Intestinal Cells
Serum LDL levels are determined by a balance between rates of production and clearance of LDLs
from the circulation, where not only the liver, but also the intestine plays a key role [28]. For this reason,
more and more attention is currently paid to the potential health benefits of lowering intestinal lipid
absorption, in view of the impact on postprandial lipoprotein metabolism and atherosclerosis [33],
although the complex molecular mechanisms underlying cholesterol homeostasis in the small intestine
have not been completely elucidated yet.
The present study provides evidence that lupin peptides are able to up-regulate LDLR through
activation of SREBP2 in intestinal cells either cultured alone or in co-culture system in temporal and
spatial proximity with human hepatic HepG2 cells. Figures 3 and 4 indicate that the treatment of
Caco-2 cells with lupin peptides produced slightly better effects on the LDLR pathway in the co-culture
system than when Caco-2 cells were treated alone. These findings suggest that the cross talk between
the intestine and hepatic system can improve the effects of lupin peptides on cholesterol metabolism
through LDLR protein up-regulation.
The LDLR expression and localization at the cellular membranes are strictly correlated with the
pathway of cholesterol biosynthesis. In fact, the transcription of LDLR and the genes required for
cholesterol and fatty acid synthesis are controlled by membrane-bound transcription factors called
SREBPs [34] and the levels of intracellular cholesterol act through a negative feedback inhibition
mechanism [35]. The SREBP2 isoform is responsible for LDLR and HMGCoAR transcription and
SREBP2 maturation is regulated by intracellular cholesterol homeostasis. Thus, LDLR up-regulation
in intestinal cells may represent a useful strategy to contribute to the control of plasma LDL
cholesterol levels. Different studies have established that the LDLR is predominantly localized at the
BL membrane of polarized well differentiated Caco-2 cells [36,37], in agreement to its localization in
mature enterocytes.
In accordance with SREBP2 activation, both peptic and tryptic lupin peptides determined an
increase of HMGCoAR protein levels. This enzyme is among the most highly regulated ones [38],
since it is long-term regulated by the control of its synthesis and degradation and short-term
regulated through phosphorylation or dephosphorylation [39]. In particular, the phosphorylation
of Ser872 by 51-adenosine monophosphate-activated protein kinase (AMPK) decreases the enzyme
activity [40]. The immunoblotting results indicate that lupin peptides induce an increase of the
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inactive phosphorylated form of HMGCoAR that can account for most of the observed increase in
total HMGCoAR induced by lupin peptides (Figure 4b,c).
Numerous studies have pointed out the importance of the regulation of LDLR by PCSK9 in the
liver [41], which has emerged as a promising target for new cholesterol-lowering therapy. In this
context, we have recently demonstrated that peptic and tryptic lupin peptides are able to decrease the
PCSK9 protein levels as well as to reduce the HNF1-alpha protein levels in human hepatic HepG2
cells [21]. Stimulated by some recent studies underlining the importance of PCSK9 in the intestine [36],
in this work, we have investigated the effects of lupin peptides treatment on the production of PCSK9
in Caco-2 cells. In particular, recent studies performed on Caco-2 cells underline that PCSK9 play
an important role in intestinal triglyceride-rich apoB lipoprotein production [42] and postprandial
lipaemia [43]. Moreover, recent evidences clearly suggest that PCSK9 is implicated in the modulation
of TICE [30]. The ability of intestinal cells to acquire cholesterol is modulated in part by Niemann-Pick
C1-Like 1 (NPC1L1) mediated luminal cholesterol uptake and, on the BL side, by the uptake of
LDL particles, a process dependent on LDLR activity. Notably, PCSK9´/´ mice were shown to
have increased fecal cholesterol excretion, whereas intravenous injection of recombinant PCSK9 acutely
in these mice reduced TICE by 35% [44]. Conversely, PCSK9 administration had no effect on TICE in
LDLR knockout mice. This observation, together with the finding that wild-type mice treated with
lovastatin for 10 days experienced a 71% increase in TICE, provides evidence that TICE modulation
by PCSK9 is dependent on LDLR expression [44]. Although the functional role of intestinal LDLR in
lipoprotein metabolism remains to be established, these findings suggest that targeting PCSK9 holds
promise for the amelioration of postprandial hypertriglyceridaemia. In line with this evidence, lupin
peptides decreased the secretion of PCSK9 in the BL medium, i.e., on the side where the LDLR proteins
are located. This preferential BL delivery of PCSK9 suggests that this protein may directly affect the
LDLR, even if the reduction of mature PCSK9 secretion was achieved without altering intracellular
PCSK9 protein levels.
5. Conclusions
In conclusions, this work has implemented a detailed investigation on the favorable effects of lupin
peptides on cholesterol metabolism in enterocytes and in a co-culture system including enterocytes
and hepatocytes. The Caco-2 cell model has proved appropriate for investigating the in vitro effects
of lupin peptides on the LDLR/SREBP2 pathway in the intestine. In addition, the co-culture system
has allowed a more physiological approach to the study of the response of hepatocytes to molecules
coming from the diet, taking into account the selective effects of transport and metabolism across the
intestinal mucosa. To the best of our knowledge, this is the first application of this co-culture system to
investigate transport and metabolic effects of peptides deriving from plant protein hydrolysis.
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AP apical
BL basolateral
BSA bovine serum albumin
DMEM Dulbecco’s modified Eagle’s medium
Nutrients 2016, 8, 437 11 of 14
FBS Foetal bovine serum
HMGCoAR 3-hydroxy-3-methylglutaryl coenzyme A reductase
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PCSK9 proprotein convertase subtilisin/kexin type 9
SREBP-2 sterol regulatory element binding proteins 2
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Figure A1. Effects of peptic and tryptic lupin peptides on the phosphorylation level of HMGCoAR
in HepG2 cells. (a) Western blots; (b) percentage change of pHMGCoAR protein expression after
treatment with peptic peptides (P) or tryptic peptides (T), C = control treatment.
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